Blair William & Co. IL Sells 48,719 Shares of IDEXX Laboratories, Inc. $IDXX

Blair William & Co. IL lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,031,786 shares of the company’s stock after selling 48,719 shares during the quarter. IDEXX Laboratories makes up approximately 1.8% of Blair William & Co. IL’s holdings, making the stock its 8th biggest holding. Blair William & Co. IL owned about 1.29% of IDEXX Laboratories worth $659,197,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Empowered Funds LLC boosted its stake in IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $265,000. Crestwood Advisors Group LLC lifted its stake in shares of IDEXX Laboratories by 3.7% in the 2nd quarter. Crestwood Advisors Group LLC now owns 860 shares of the company’s stock valued at $461,000 after purchasing an additional 31 shares during the period. Moors & Cabot Inc. bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth $228,000. Finally, Resona Asset Management Co. Ltd. boosted its position in shares of IDEXX Laboratories by 4.7% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 28,079 shares of the company’s stock worth $15,038,000 after purchasing an additional 1,255 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on IDXX shares. UBS Group dropped their price objective on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Barclays reduced their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $783.33.

Insider Buying and Selling

In related news, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares of the company’s stock, valued at $7,963,334.34. This represents a 29.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 45,957 shares of company stock valued at $29,862,109. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Down 1.7%

IDEXX Laboratories stock opened at $608.41 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The company’s 50-day moving average is $666.94 and its 200-day moving average is $668.20. The firm has a market capitalization of $48.44 billion, a PE ratio of 46.55, a P/E/G ratio of 3.76 and a beta of 1.66. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.